Milliman MedInsight Achieves ONC Certification, Advancing Value-Based Care Solutions in Healthcare
- Milliman MedInsight secures ONC certification for electronic Clinical Quality Measures, enhancing compliance and patient care.
- The certification validates Milliman MedInsight’s commitment to quality and security in healthcare technology solutions.
- Milliman MedInsight aims to improve clinical data integration, focusing on value-based care and healthcare transformation.
Milliman MedInsight Advances Value-Based Care with ONC Certification
Milliman MedInsight, a leading player in healthcare data and analytics, begins 2026 with significant momentum as it intensifies its commitment to value-based care. The organization recently secures certification from the Office of the National Coordinator for Health Information Technology (ONC) for its electronic Clinical Quality Measures (eCQM) as part of the Health IT Certification Program. This prestigious certification validates that Milliman MedInsight's solutions adhere to essential federal standards regarding capability, functionality, and security. As a result, this development simplifies reporting processes for healthcare organizations while enhancing patient care and ensuring compliance with regulatory requirements.
The ONC certification stands as a testament to Milliman MedInsight's dedication to quality and security in healthcare technology. Nicole Zilliox, the Director of Clinical Products at Milliman MedInsight, expresses pride in this achievement, emphasizing that it offers third-party validation of their solutions' effectiveness in supporting healthcare organizations with accurate eCQM and clinical data reporting. This certification not only reassures clients but also strengthens Milliman’s position as a trusted partner in navigating the complexities of healthcare reporting and compliance.
As part of its broader vision, Milliman MedInsight aims to empower healthcare providers, payers, and public health agencies through enhanced clinical data integration. This strategic focus involves consolidating data from diverse sources, including electronic health records (EHRs), claims, laboratories, and admission/discharge/transfer (ADT) systems. Rich Moyer, Chief Product Officer, highlights the critical role of reliable and timely data in transforming healthcare performance. Looking ahead, Milliman MedInsight plans to leverage its ONC certification and advanced integration strategies to facilitate actionable insights for healthcare organizations, promoting both clinical excellence and operational efficiency in an increasingly dynamic healthcare landscape.
Strategic Goals and Future Directions
Milliman MedInsight's commitment to enhancing clinical data integration is set to lead to significant improvements in care quality, operational efficiency, and financial performance for healthcare providers. By focusing on value-based care, the organization positions itself as a critical player in the ongoing transformation of healthcare delivery systems.
The ONC certification not only fortifies Milliman MedInsight's reputation but also aligns with its mission to drive innovation in healthcare technology. As the industry evolves, the company plans to stay at the forefront, harnessing data to improve patient outcomes and streamline healthcare operations.
Related Cashu News

CRISPR Therapeutics AG Achieves Financial Progress Amid Advancements in Gene-Editing Portfolio
CRISPR Therapeutics AG (Ticker: UNDEFINED) showcases a pivotal moment in its financial journey with the release of its results for the first quarter of 2026. Highlighting a revenue of $1.46 million, t…

MetaVia to Present Innovative Cardiometabolic Research at 2026 ADA Scientific Sessions
MetaVia is set to showcase its innovative research in cardiometabolic diseases at the upcoming American Diabetes Association (ADA) Scientific Sessions in 2026, following the acceptance of three late-b…

Ionis Pharmaceuticals Advances TRYNGOLZA for Hypertriglyceridemia and Diranersen for Alzheimer's Disease
Ionis Pharmaceuticals has made headlines in the biotechnology sector with the promising potential of its drug TRYNGOLZA, which is designed to treat severe hypertriglyceridemia. During a recent healthc…

ImmunityBio Partners with BCG Laboratory to Enhance Bladder Cancer Treatment Supply and Options
ImmunityBio has secured a critical partnership with Japan's BCG Laboratory to enhance the supply of Bacillus Calmette-Guérin (BCG) in the United States, addressing an urgent need in the treatment of b…